Miia K. Kivipelto (born 1973) is a Finnish neuroscientist and professor at the University of Eastern Finland and Karolinska Institute in Stockholm. Her research focuses on dementia and Alzheimer's disease.
Miia K. Kivipelto (born 1973) is a Finnish neuroscientist and professor at the University of Eastern Finland and Karolinska Institute in Stockholm. Her research focuses on dementia and Alzheimer's disease.
Kivipelto was born in Alajärvi, Finland in 1973. She studied medicine at the University of Kuopio (now University of Eastern Finland) and received her MD in 1999, specializing in geriatrics. She received her PhD in 2002 after defending her dissertation on vascular risk factors in Alzheimer's disease. In a 2017 interview, Kivipelto attributed her interest in dementia, Alzheimer's, and diseases of aging to her close relationship with her grandmother, who developed Alzheimer's when she was young. [1]
Kivipelto held a post-doctoral fellowship at the Karolinska Institute from 2002–2005. [2] In 2006, Kivipelto was appointed associate professor of neuroepidemiology at the University of Kuopio. Kivipelto became a senior lecturer at the Karolinska Institute (KI) in 2010 and was appointed professor of clinical geriatric epidemiology there in 2011. She is a deputy director of the KI Aging Research Center and the KI Memory Clinic clinical trial unit at the Karolinska University Hospital in Huddinge. [2]
Kivipelto studies the epidemiology, prevention, and treatment of dementia, which is a decline in cognitive function strongly associated with ageing and neurodegenerative diseases such as Alzheimer's disease. Her research has identified connections between memory disorders and vascular risk factors such as high blood lipids and high blood pressure, as well as general health risk factors such as poor physical fitness and obesity. [2] Kivipelto published a composite risk score to predict dementia risk based on these factors in 2006 following the Cardiovascular Risk Factors, Aging, and Dementia (CAIDE) population-based study. [3]
From 2009–2011, Kivipelto led the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) clinical trial, which demonstrated that a multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring may preserve cognitive functioning in elderly people with high dementia risk. [1] [4] She currently leads the World Wide FINGERS initiative, which aims to replicate multi-domain dementia prevention trials and share data internationally. [5]
Kivipelto has received several awards for her work:
Dementia is the general name for a decline in cognitive abilities that impacts a person's ability to perform everyday activities. This typically involves problems with memory, thinking, and behavior. Aside from memory impairment and a disruption in thought patterns, the most common symptoms include emotional problems, difficulties with language, and decreased motivation. The symptoms may be described as occurring in a continuum over several stages. Dementia ultimately has a significant effect on the individual, caregivers, and on social relationships in general. A diagnosis of dementia requires the observation of a change from a person's usual mental functioning and a greater cognitive decline than what is caused by normal aging.
Vascular dementia (VaD) is dementia caused by problems in the blood supply to the brain, resulting from a cerebrovascular disease. Restricted blood supply (ischemia) leads to cell and tissue death in the affected region, known as an infarct. The three types of vascular dementia are subcortical vascular dementia, multi-infarct dementia, and stroke related dementia. Subcortical vascular dementia is brought about by damage to the small blood vessels in the brain. Multi-infarct dementia is brought about by a series of mini-strokes where many regions have been affected. The third type is stroke related where more serious damage may result. Such damage leads to varying levels of cognitive decline. When caused by mini-strokes, the decline in cognition is gradual. When due to a stroke, the cognitive decline can be traced back to the event.
Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. It appears to result in a small benefit in mental function and ability to function. Use, however, has not been shown to change the progression of the disease. Treatment should be stopped if no benefit is seen. It is taken by mouth or via a transdermal patch.
Memory disorders are the result of damage to neuroanatomical structures that hinders the storage, retention and recollection of memories. Memory disorders can be progressive, including Alzheimer's disease, or they can be immediate including disorders resulting from head injury.
The prevention of dementia involves reducing the number of risk factors for the development of dementia, and is a global health priority needing a global response. Initiatives include the establishment of the International Research Network on Dementia Prevention (IRNDP) which aims to link researchers in this field globally, and the establishment of the Global Dementia Observatory a web-based data knowledge and exchange platform, which will collate and disseminate key dementia data from members states. Although there is no cure for dementia, it is well established that modifiable risk factors influence both the likelihood of developing dementia and the age at which it is developed. Dementia can be prevented by reducing the risk factors for vascular disease such as diabetes, high blood pressure, obesity, smoking, physical inactivity and depression. A study concluded that more than a third of dementia cases are theoretically preventable. Among older adults both an unfavorable lifestyle and high genetic risk are independently associated with higher dementia risk. A favorable lifestyle is associated with a lower dementia risk, regardless of genetic risk. In 2020, a study identified 12 modifiable lifestyle factors, and the early treatment of acquired hearing loss was estimated as the most significant of these factors, potentially preventing up to 9% of dementia cases.
Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens, and is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events. As the disease advances, symptoms can include problems with language, disorientation, mood swings, loss of motivation, self-neglect, and behavioral issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.
Perminder Sachdev is an Indian neuropsychiatrist based in Australia. He is a professor of neuropsychiatry at the University of New South Wales (UNSW), co-director of the UNSW Centre for Healthy Brain Aging, and clinical director of the Neuropsychiatric Institute at the Prince of Wales Hospital, Sydney. He is considered a trailblazer in the field of neuropsychiatry. Sachdev's research interests include ageing, vascular cognitive disorders such as vascular dementia, and psychiatric disorders.
Ryman Healthcare Limited is a New Zealand retirement village and rest home operator. It is listed on the New Zealand Stock Exchange and is one of the largest companies listed on the NZX 50 Index.
Monique Maria Bernadette Breteler is a Dutch neuroepidemiologist. She is Director of Population Health Sciences at the German Center for Neurodegenerative Diseases (DZNE), Professor of Population Health Sciences at the University of Bonn, and Adjunct Professor of Epidemiology at the Harvard School of Public Health in Boston, Massachusetts. She has been a foreign member of the Royal Netherlands Academy of Arts and Sciences since 2015.
Cerebrolysin is a mixture of enzymatically treated peptides derived from pig brain whose constituents can include brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF).
Vladimir Hachinski is a Canadian clinical neuroscientist and researcher based at the Schulich School of Medicine and Dentistry at Western University. He is also a Senior Scientist at London's Robarts Research Institute. His research pertains in the greatest part to stroke and dementia, the interactions between them and their joint prevention. He and John W. Norris helped to establish the world's first successful stroke unit at Sunnybrook Hospital in Toronto, and, by extension, helped cement stroke units as the standard of care for stroke patients everywhere. He discovered that the control of the heart by the brain is asymmetric, the fight/flight (sympathetic) response being controlled by the right hemisphere and the rest and digest (parasympathetic) response being controlled by the left hemisphere and damage to one key component can lead to heart irregularities and sudden death. This discovery has added fundamental knowledge to how the brain controls the heart and blood pressure and lays the foundation for helping prevent sudden death.
Geriatric psychology is a subfield of psychology that specializes in the mental and physical health of individuals in the later stages of life. These specialized psychologists study a variety of psychological abilities that deplete as aging occurs such as memory, learning capabilities, and coordination. Geriatric psychologists work with elderly clients to conduct the diagnosis, study, and treatment of certain mental illnesses in a variety of workplace settings. Common areas of practice include loneliness in old age, depression, dementia, Alzheimer's disease, vascular dementia, and Parkinson's disease.
Clive Ballard is a British, world-leading expert in dementia. He is currently Professor of Age-Related Diseases at the University of Exeter and Interim Deputy Pro-Vice-Chancellor and Dean of the University of Exeter Medical School.
Rebecca Gottesman is Senior Investigator and Stroke Branch Chief at the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH). Before joining NINDS, she was Professor of Neurology and Epidemiology at Johns Hopkins University. Gottesman completed a B.A. in Psychology at Columbia University (1995), an M.D. at Columbia University (2000), and a Ph.D. in Clinical Investigation at Johns Hopkins University (2007). She is a Fellow of the American Neurological Association (2012) and a Fellow of the American Heart Association (2015).
Dementia and Alzheimer's disease in Australia is a major health issue. Alzheimer's disease is the most common type of dementia in Australia. Dementia is an ever-increasing challenge as the population ages and life expectancy increases. As a consequence, there is an expected increase in the number of people with dementia, posing countless challenges to carers and the health and aged care systems. In 2018, an estimated 376,000 people had dementia; this number is expected to increase to 550,000 by 2030 and triple to 900,000 by 2050. The dementia death rate is increasing, resulting in the shift from fourth to second leading cause of death from 2006 to 2015. It is expected to become the leading cause of death over the next number of years. In 2011, it was the fourth leading cause of disease burden and third leading cause of disability burden. This is expected to remain the same until at least 2020.
Gladys Elena Maestre is a neuroscientist from Venezuela who is a professor at the University of Texas Rio Grande Valley School of Medicine. She is known for her work on Alzheimer's disease and other forms of dementia.
Hypertension is a condition characterized by an elevated blood pressure in which the long term consequences include cardiovascular disease, kidney disease, adrenal gland tumors, vision impairment, memory loss, metabolic syndrome, stroke and dementia. It affects nearly 1 in 2 Americans and remains as a contributing cause of death in the United States. There are many genetic and environmental factors involved with the development of hypertension including genetics, diet, and stress.
Jennifer J. Manly is an American neuropsychologist. She is a Professor of Neuropsychology in Neurology at the Gertrude H. Sergievsky Center and the Taub Institute for Research in Aging and Alzheimer's Disease at Columbia University. Manly studies how race, culture, socioeconomic status, and education influence the risk of cognitive decline in aging.
Alexa S. Beiser is an American professor of biostatistics and public health researcher.
| International | |
|---|---|
| Academics | |
